Dasatinib, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastatic melanoma. Its named after Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.
Recently, researchers with UCLA's Jonsson Comprehensive Cancer Center found that Sprycel, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death. The drug, when paired with a chemotherapy regimen, was even more effective in fighting ovarian cancer in cell lines in which signaling of the Src family kinases, associated with the deadly disease, is activated. The researchers are excited because of the fact that "recent gene expression studies have shown that about one-third of women have ovarian cancers with activated Src pathways", so the drug could potentially help 7,000 ovarian cancer patients every year. Gottfried Konecny (lead researcher) said, it also inhibits the focal adhesion kinase and ephrin receptor, (drug is known to inhibit in many pathways) also associated with ovarian cancer. Though clinical trials are still to be established , its a remarkable achievement. More details .....
Recently, researchers with UCLA's Jonsson Comprehensive Cancer Center found that Sprycel, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death. The drug, when paired with a chemotherapy regimen, was even more effective in fighting ovarian cancer in cell lines in which signaling of the Src family kinases, associated with the deadly disease, is activated. The researchers are excited because of the fact that "recent gene expression studies have shown that about one-third of women have ovarian cancers with activated Src pathways", so the drug could potentially help 7,000 ovarian cancer patients every year. Gottfried Konecny (lead researcher) said, it also inhibits the focal adhesion kinase and ephrin receptor, (drug is known to inhibit in many pathways) also associated with ovarian cancer. Though clinical trials are still to be established , its a remarkable achievement. More details .....
